ClinicalTrials.gg
RecruitingNCT06338943MAPO-HFUpdated Apr 1, 2024

Middle-aged Women With Adverse Pregnancy Outcomes and Heart Failure With Preserved Ejection Fraction

An observational study in Heart Failure Preserved Ejection Fraction and Pregnancy Complications, sponsored by National Medical Research Center for Therapy and Preventive Medicine. Recruiting at 1 site in Russian Federation. Open to female participants aged 45 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-04-01.

Sponsored by National Medical Research Center for Therapy and Preventive Medicine · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
100
Ages
45 Years to 60 Years
Sex
Female
01

Study summary

Due to the steady increase in the burden of HFpEF, especially in women, it is an important task to search for new markers and early predictors associated with the development of this disease. Nowadays, the relationship of adverse pregnancy factors with the development of long-term cardiac pathology, in particular, HFpEF, has not been completely established. One of the most significant issue is studying the younger phenotype of women.

The goal of this observational analytical cross-sectional study is to study the relationship of heart failure with a preserved ejection fraction in middle-aged women with adverse pregnancy outcomes in the history of pregnancy.

Research question: is there an association between adverse pregnancy factors and the development of HF in middle-aged women?

Objectives

  1. To assess the frequency of detection of APOs in the history of pregnancy in middle-aged women, depending on the presence or absence of HFpEF.
  2. To compare clinical and anamnestic data, morphological and functional parameters of the heart in middle-aged women with the presence and absence of HFpEF.
  3. To establish an association between APOs and the development of HFpEF in the long-term period in middle-aged women.
  4. To identify mediators between the presence of APOs and the development of HFpEF in middle-aged women.

Study population - 45-60 year-old women with the history of pregnancy (>20 weeks) in the absence of low left ventricle ejection fraction (\<50%)

Primary endpoint: The prevalence of HFpEF in patients with the history of APOs.

Read the detailed description

Heart failure (HF) occupies a special place in the structure of cardiological pathology. This is largely due to the active modernization of approaches to the diagnosis of HF - every year the possibilities of cardiac imaging increase significantly, which leads to dynamic changes in the criteria for diagnosis. To the greatest extent, these changes affect heart failure with a preserved ejection fraction (HFpEF; left ventricular ejection fraction ≥ 50%), the importance of which is steadily growing with increasing life expectancy, obesity and cardiometabolic disorders. If in the recent past, HF was perceived not as independent disease, which is a complication of the underlying cardiac pathology, today, due to the increasing detectability of HFpEF, the latter can be considered as a separate multifactorial disease. Patients with HFpEF make up about half of the population of patients with HF, which, together with difficulties in understanding the pathophysiological mechanisms of the disease, is a significant problem for clinical practice.

Due to the steady increase in the burden of HFpEF, especially in women, it is an important task to search for new markers and early predictors associated with the development of this disease. This area of scientific activity has become especially popular in recent years in both world and domestic cardiology. The leading causes of the development of HFpEF are old age, obesity, coronary heart disease and pulmonary hypertension. A significant association has also been established with such markers as female gender, diabetes mellitus (DM), chronic kidney disease (CKD), alcohol abuse, arterial hypertension, smoking and others. Important issue now is the study of the association of pregnancy factors and its complications with the development of various forms of HF in both early and long-term periods. It is known that significant changes in a woman's body during pregnancy contribute to the development of important structural and hemodynamic changes in the cardiovascular system, which, in the absence of predisposing adverse factors, are in most cases reversible. Unfortunately, pathology detected during pregnancy is also often a trigger factor for the formation of structural remodeling of the heart and blood vessels, which can lead to the development of HF in the long term after pregnancy.

Despite the presence of large foreign studies reflecting the high incidence of various forms of chronic non-communicable diseases in women with adverse in the gestational period, the relationship of adverse pregnancy outcomes (APOs) with the development of long-term cardiac pathology, in particular, HFpEF, has not been sufficiently studied. Moreover, approaches to the diagnosis of HFpEF vary significantly, there are often no diagnostic protocols in the studies. In such works, a universal approach is more frequently used without dividing patients into phenotypes, depending on age and comorbidity ("one-size-fits-all approach"), which is critically important in assessing such a heterogeneous disease. The above factors make the interpretation of the data and conclusions ambiguous.

To date, the issue of the association of adverse pregnancy factors with the development of HFpEF in the long-term period is unsolved. It is particularly interesting to study the younger phenotype of patients due to the greater detectability of HFpEF in this group of individuals in Russia compared with Western countries. Studying the nature of this relationship will expand understanding of the role of different APOs in the development of structural and functional changes of the heart in a woman's future.

02

Conditions studied

  • Heart Failure Preserved Ejection Fraction
  • Pregnancy Complications

Keywords

  • Heart Failure Preserved Ejection Fraction
  • Adverse Pregnancy Outcomes
  • Arterial Hypertension
  • Gestational Diabetes
  • Mediation
03

In context

Heart Failure, Diastolic

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

This study's planned enrollment of 100 is below the median of 200 across 55 observational studies indexed under Heart Failure, Diastolic.

Browse Heart Failure, Diastolic studies →

Lead sponsor

National Medical Research Center for Therapy and Preventive Medicine is the lead sponsor of 29 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Generic Moscow population

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients who administer to the Federal State Budgetary Institution National Medical Research Center for Therapy and Preventive Medicine, who are undergoing echocardiography for medical reasons
  • Pregnancy >20 weeks in the anamnesis
  • Signed to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Refusal to sign an to participate in a clinical trial and to process personal data
  • Detection of left ventricle \< 50% according to Echocardiography data
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient with the history of pregnancy

    Patient with the history of pregnancy (1 or more \> 20 weeks) This group will further be subdivided in a subgroup with HFpEF and a group without HFpEF

    Diagnostic Test: Echocardiography · Other: Questionnaire

Interventions

  • Diagnostic testEchocardiography

    Echocardiography to diagnose HFpEF

  • OtherQuestionnaire

    Questionnaire to determine the presence of adverse pregnancy outcomes history

06

What researchers measure

Primary outcomes

  1. HFpEF incidence

    Heart Failure with Preserved Ejection Fraction will be assessed with the transthoracic echocardiography based on the criteria of American Heart Association guidelines, where left ventricle ejection fraction \> 50%.

    Time frame: on enrollment

  2. APOs incidence

    Adverse pregnancy outcomes will be determined by means of questionnaire

    Time frame: on enrollment

07

Study locations

1 of 1 sites recruiting
  • National Medical Research Center for Therapy and Preventive Medicine
    Moscow, Russian Federation
    Recruiting
    • Olga Dzhioeva, MD, PhD · Contactodzhioeva@gnicpm.ru · +79166141821
    • Max Shperling, MD · Principal investigator
    • Alexandr Mols · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Jan 2025, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2024
First posted
Apr 1, 2024
StartActual
Mar 18, 2024
Primary completionEst.
Jan 2025
CompletionEst.
Jan 2025
Last update
Apr 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06338943
Lead sponsor
National Medical Research Center for Therapy and Preventive Medicine
Responsible party
Sponsor
First posted
Apr 1, 2024
Start date
Mar 18, 2024
Primary completion
Jan 2025 (estimated)
Completion
Jan 2025 (estimated)
Last update
Apr 1, 2024

Study contacts

Max Shperling, MD
Contact
MaxCardio@yandex.ru
+79118170034
Olga Dzhioeva, MD, PhD
Contact
odzhioeva@gnicpm.ru
+79166141821
Olga Dzhioeva, MD, PhD
study director · National Medical Research Center for Therapy and Preventive Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion